Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million October 24, 2024
Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases August 1, 2024